Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Details 1)

v2.4.0.8
Fair Value Measurements (Details 1) (Fair Value, Measurements, Recurring [Member], USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Assets:    
Total assets $ 169,859 $ 31,684
Liabilities:    
Total liabilities 152,400 30,169
Common stock investments, available for sale [Member]
   
Assets:    
Total assets 2,536 8,236
Level 1 [Member]
   
Assets:    
Total assets 107,718 26,952
Level 1 [Member] | Common stock investments, available for sale [Member]
   
Assets:    
Total assets 2,536 8,236
Level 2 [Member]
   
Assets:    
Total assets 60,101 2,692
Liabilities:    
Total liabilities 0 10
Level 3 [Member]
   
Assets:    
Total assets 2,040 2,040
Liabilities:    
Total liabilities 152,400 30,159
Forward contracts [Member]
   
Liabilities:    
Total liabilities   10
Forward contracts [Member] | Level 2 [Member]
   
Liabilities:    
Total liabilities   10
Embedded conversion option [Member]
   
Liabilities:    
Total liabilities 74,079  
Embedded conversion option [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 74,079  
Deferred acquisition payments, net of discount [Member]
   
Liabilities:    
Total liabilities 9,415 10,103
Deferred acquisition payments, net of discount [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 9,415 10,103
CURNA [Member]
   
Liabilities:    
Total liabilities 549 510
CURNA [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 549 510
OPKO Diagnostics [Member]
   
Liabilities:    
Total liabilities 14,512 12,974
OPKO Diagnostics [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 14,512 12,974
FineTech [Member]
   
Liabilities:    
Total liabilities 2,763 5,262
FineTech [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 2,763 5,262
Cytochroma [Member]
   
Liabilities:    
Total liabilities 49,784  
Cytochroma [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 49,784  
Farmadiet [Member]
   
Liabilities:    
Total liabilities 1,298 1,310
Farmadiet [Member] | Level 3 [Member]
   
Liabilities:    
Total liabilities 1,298 1,310
Money market funds [Member]
   
Assets:    
Total assets 80,183 18,716
Money market funds [Member] | Level 1 [Member]
   
Assets:    
Total assets 80,183 18,716
US Treasury Securities [Member]
   
Assets:    
Total assets 75,026  
US Treasury Securities [Member] | Level 1 [Member]
   
Assets:    
Total assets 24,999  
US Treasury Securities [Member] | Level 2 [Member]
   
Assets:    
Total assets 50,027  
Certificates of Deposit [Member]
   
Assets:    
Total assets 827 820
Certificates of Deposit [Member] | Level 2 [Member]
   
Assets:    
Total assets 827 820
Forward Contracts [Member]
   
Assets:    
Total assets 133  
Forward Contracts [Member] | Level 2 [Member]
   
Assets:    
Total assets 133  
Neovasc common stock options [Member]
   
Assets:    
Total assets 2,319 1,394
Neovasc common stock options [Member] | Level 2 [Member]
   
Assets:    
Total assets 2,319 1,394
Current portion of lines of credit and notes payable [Member] | BZNE Note and conversion feature [Member]
   
Assets:    
Total assets 2,040 2,040
Current portion of lines of credit and notes payable [Member] | Level 3 [Member] | BZNE Note and conversion feature [Member]
   
Assets:    
Total assets 2,040 2,040
Warrant [Member]
   
Assets:    
Total assets   478
Warrant [Member] | Level 2 [Member]
   
Assets:    
Total assets   478
Notes Receivable [Member]
   
Assets:    
Total assets 6,795  
Notes Receivable [Member] | Level 2 [Member]
   
Assets:    
Total assets $ 6,795